Kalvista Pharmaceuticals Inc (NASDAQ:KALV) major shareholder Svlsf Iv, Llc sold 22,800 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $29.49, for a total transaction of $672,372.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Svlsf Iv, Llc also recently made the following trade(s):

  • On Tuesday, March 26th, Svlsf Iv, Llc sold 30,093 shares of Kalvista Pharmaceuticals stock. The shares were sold at an average price of $29.70, for a total transaction of $893,762.10.
  • On Monday, March 4th, Svlsf Iv, Llc sold 43,378 shares of Kalvista Pharmaceuticals stock. The shares were sold at an average price of $22.91, for a total transaction of $993,789.98.

KALV opened at $29.19 on Thursday. Kalvista Pharmaceuticals Inc has a fifty-two week low of $7.73 and a fifty-two week high of $34.92. The stock has a market capitalization of $503.53 million, a P/E ratio of -19.08 and a beta of 2.49.

Kalvista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.23) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.22. Kalvista Pharmaceuticals had a negative net margin of 70.08% and a negative return on equity of 19.12%. The company had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.97 million. Analysts expect that Kalvista Pharmaceuticals Inc will post -1.43 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of KALV. Vanguard Group Inc raised its holdings in shares of Kalvista Pharmaceuticals by 152.4% in the 3rd quarter. Vanguard Group Inc now owns 296,581 shares of the specialty pharmaceutical company’s stock worth $6,558,000 after acquiring an additional 179,092 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Kalvista Pharmaceuticals by 152.4% in the 3rd quarter. Vanguard Group Inc. now owns 296,581 shares of the specialty pharmaceutical company’s stock worth $6,558,000 after acquiring an additional 179,092 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of Kalvista Pharmaceuticals in the 3rd quarter worth about $3,053,000. Fosun International Ltd acquired a new stake in shares of Kalvista Pharmaceuticals in the 4th quarter worth about $2,444,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Kalvista Pharmaceuticals by 228.5% in the 3rd quarter. Renaissance Technologies LLC now owns 117,349 shares of the specialty pharmaceutical company’s stock worth $2,595,000 after acquiring an additional 81,621 shares during the last quarter. Institutional investors own 77.22% of the company’s stock.

Several equities analysts have recently weighed in on KALV shares. Zacks Investment Research lowered shares of Kalvista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 21st. BidaskClub lowered shares of Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 17th. TheStreet upgraded shares of Kalvista Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Thursday, December 20th. Needham & Company LLC started coverage on shares of Kalvista Pharmaceuticals in a report on Wednesday, March 20th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, ValuEngine upgraded shares of Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Kalvista Pharmaceuticals has an average rating of “Buy” and an average target price of $28.60.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/kalvista-pharmaceuticals-inc-kalv-major-shareholder-svlsf-iv-llc-sells-22800-shares/2954663.html.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Story: Total Return

Insider Buying and Selling by Quarter for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.